





Maintenance therapy with TKIs in High Grade advanced Uterine Sarcoma ?




A randomized double-blind phase II study evaluating the role of maintenance therapy with **cabozantinib** in Uterine Sarcoma (HG) after stabilization or response to **doxorubicin +/- ifosfamide** following surgery or in metastatic first line treatment



EORTC 62113-55115 (registered n = 54, randomized, n = 20)

Accrual: Randomization



Institution	# Registered	# Randomized
Centre Leon Berard (227)	22	5
Centre Georges-Francois-Leclerc (229)	3	2
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre (6982)	2	2
Royal Marsden Hospital - Chelsea, London (613)	2	2
Hospital Universitario San Carlos (366)	3	2
Fondazione IRCCS Istituto Nazionale dei Tumori (704)	3	2
Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau (235)	7	1
Cambridge University Hospital NHS - Addenbrookes Hospital (632)	3	1
Academisch Medisch Centrum - Universiteit van Amsterdam (342)	1	1
Hospital General Vall D'Hebron (371)	1	1
Universitair Ziekenhuis Antwerpen (117)	1	0
Nottingham City Hospital (6998)	1	0
Churchill Oxford (619)	1	0
Total	50	19

As per protocol a safety evaluation has been done on 6 patients that have completed two cycles of Cabozantinib. The aim was to evaluate if the initial dose of 60 mg of Cabozantinib was sufficiently tolerable. The conclusion of this review was that there are no concerns and the study can continue recruitment as it is.